Company Description
Roche Holding AG operates as a research healthcare company. It operates through the following divisions: Pharmaceuticals and Diagnostics. The Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four busin...
Roche Holding AG operates as a research healthcare company. It operates through the following divisions: Pharmaceuticals and Diagnostics. The Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
Valuation
P/E Current
18.32
P/E Ratio (with extraordinary items)
18.31
P/E Ratio (without extraordinary items)
14.31
Enterprise Value to EBITDA
11.10
Enterprise Value to Sales
3.86
Efficiency
Liquidity
Cash Ratio
0.36
Profitability
Net Margin
21.38
Capital Structure
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Dr. Severin Schwan | 54 | 2008 | Chief Executive Officer |
Dr. Alan Hippe | 54 | 2011 | Chief Financial Officer |
Dr. Levi A. Garraway | - | - | Chief Medical Officer |
Dr. Gallia G. Levy | - | - | Associate Group Medical Director-Hematology |
Ms. Pascale Schmidt | 47 | 2020 | Chief Compliance Officer |
Insider Actions
10/19/2022 |
DIRECTOR Swiss Non EXECUTIVE |
610 | Acquisition at $328.68 per share. | 200,493 |
05/13/2022 |
Executive Officer Swiss |
1 | Acquisition at $319 per share. | 319 |
05/13/2022 |
Executive Officer Swiss |
1 | Acquisition at $319 per share. | 319 |
05/13/2022 |
Executive Officer Swiss |
1 | Acquisition at $319 per share. | 319 |
05/13/2022 |
Executive Officer Swiss |
1 | Acquisition at $319 per share. | 319 |
05/11/2022 |
Executive Officer Swiss |
1,500 | Acquisition at $326.78 per share. | 490,162 |
03/30/2022 |
Executive Officer Swiss |
1,624 | Disposition at $373.14 per share. | 605,971 |
03/30/2022 |
Executive Officer Swiss |
1,624 | Disposition at $373.14 per share. | 605,971 |
12/16/2021 |
Executive Officer Swiss |
19,920 | Disposition at $379.95 per share. | 7,568,627 |
12/16/2021 |
Executive Officer Swiss |
19,920 | Disposition at $379.95 per share. | 7,568,627 |
12/16/2021 |
Executive Officer Swiss |
19,920 | Derivative/Non-derivative trans. at $379.95 per share. | 7,568,627 |
12/16/2021 |
Executive Officer Swiss |
19,920 | Derivative/Non-derivative trans. at $379.95 per share. | 7,568,627 |
08/12/2021 |
Executive Officer Swiss |
3,163 | Disposition at $368.23 per share. | 1,164,698 |
08/12/2021 |
Executive Officer Swiss |
3,163 | Disposition at $368.23 per share. | 1,164,698 |
08/09/2021 |
Executive Officer Swiss |
8,788 | Acquisition at $362.2 per share. | 3,183,013 |
08/09/2021 |
Executive Officer Swiss |
8,788 | Acquisition at $362.2 per share. | 3,183,013 |
08/09/2021 |
DIRECTOR Swiss Non EXECUTIVE |
271 | Acquisition at $394.4 per share. | 106,881 |
08/09/2021 |
DIRECTOR Swiss Non EXECUTIVE |
271 | Acquisition at $394.4 per share. | 106,881 |
07/30/2021 |
Executive Officer Swiss |
4,317 | Disposition at $350 per share. | 1,510,950 |
07/30/2021 |
Executive Officer Swiss |
1,116 | Disposition at $350 per share. | 390,600 |
07/30/2021 |
Executive Officer Swiss |
4,317 | Disposition at $350 per share. | 1,510,950 |
07/30/2021 |
Executive Officer Swiss |
1,116 | Disposition at $350 per share. | 390,600 |
06/22/2021 |
Executive Officer Swiss |
500 | Disposition at $374.8 per share. | 187,400 |
06/22/2021 |
Executive Officer Swiss |
500 | Disposition at $374.8 per share. | 187,400 |
06/17/2021 |
Executive Officer Swiss |
3,000 | Disposition at $348.6 per share. | 1,045,800 |
06/17/2021 |
Executive Officer Swiss |
2,000 | Disposition at $373.13 per share. | 746,250 |
06/17/2021 |
Executive Officer Swiss |
3,000 | Disposition at $348.6 per share. | 1,045,800 |
06/17/2021 |
Executive Officer Swiss |
2,000 | Disposition at $373.13 per share. | 746,250 |
MarketWatch News on RHHVF
-
Merck & Co. Inc. stock falls Wednesday, underperforms market
- MarketWatch Automation
-
Eli Lilly & Co. stock rises Wednesday, still underperforms market
- MarketWatch Automation
-
Amgen Inc. stock underperforms Wednesday when compared to competitors
- MarketWatch Automation
-
Abbott Laboratories stock rises Wednesday, outperforms market
- MarketWatch Automation
-
Merck & Co. Inc. stock rises Tuesday, still underperforms market
- MarketWatch Automation
-
Eli Lilly & Co. stock underperforms Tuesday when compared to competitors
- MarketWatch Automation
-
Amgen Inc. stock underperforms Tuesday when compared to competitors
- MarketWatch Automation
-
Abbott Laboratories stock rises Tuesday, still underperforms market
- MarketWatch Automation
-
Merck & Co. Inc. stock outperforms competitors on strong trading day
- MarketWatch Automation
-
Eli Lilly & Co. stock falls Monday, still outperforms market
- MarketWatch Automation
-
Amgen Inc. stock underperforms Monday when compared to competitors despite daily gains
- MarketWatch Automation
-
Abbott Laboratories stock outperforms market on strong trading day
- MarketWatch Automation
-
Merck & Co. Inc. stock rises Friday, outperforms market
- MarketWatch Automation
-
Eli Lilly & Co. stock rises Friday, still underperforms market
- MarketWatch Automation
-
Amgen Inc. stock falls Friday, underperforms market
- MarketWatch Automation
-
Abbott Laboratories stock outperforms competitors on strong trading day
- MarketWatch Automation
-
Merck & Co. Inc. stock outperforms market on strong trading day
- MarketWatch Automation
-
Eli Lilly & Co. stock outperforms competitors on strong trading day
- MarketWatch Automation
-
Amgen Inc. stock rises Thursday, outperforms market
- MarketWatch Automation
-
Abbott Laboratories stock underperforms Thursday when compared to competitors
- MarketWatch Automation
- Loading more headlines...
Other News on RHHVF
-
IDNA: Healthcare Dashboard For November
- Seeking Alpha
-
Kodiak: Turnaround Strategy Has Shown Life Thus Far
- Seeking Alpha
-
Aurinia: A Commercial Stage Company With Major Headwinds
- Seeking Alpha
-
Akero: Putting Together The Pieces They Let Us See
- Seeking Alpha
-
An Overview Of Today's Alzheimer's Disease Development Field
- Seeking Alpha
-
- Seeking Alpha
-
Guardant: Saving Lives One Blood Test At A Time
- Seeking Alpha
-
IXJ Has A Shot At Earnings Growth But Is Still Too Expensive
- Seeking Alpha
-
BioMarin Pharmaceutical: Leader In Rare Disease Innovation
- Seeking Alpha
-
Roche: New Drugs Will Outpace Biosimilar Competition
- Seeking Alpha
-
Invitae Busted Business Model Offers A Tactical Opportunity
- Seeking Alpha
-
TG Therapeutics: We Are Just Hanging In There
- Seeking Alpha
-
Teva Pharmaceutical: Investment Opportunity During Fed Rate Hike
- Seeking Alpha
-
Teva Pharmaceutical: Past Behind And A Promising 2023
- Seeking Alpha
- Loading more headlines...